TabletsClinical Overview
Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once or twice daily with a glass of water, with or without meals. Maintain consistent daily timing. First dose should preferably be taken at bedtime to prevent first-dose hypotension.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Persistent dry hacking cough (due to bradykinin accumulation), dizziness, headache, fatigue, nausea, orthostatic hypotension. Rare/Severe: Boxed warning: Fetal toxicity in pregnancy; life-threatening angioedema (swelling of face, lips, tongue, larynx, gut), hyperkalemia, acute renal failure, and neutropenia/agranulocytosis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Fetal toxicity; discontinue immediately if pregnancy is detected. Absolute contraindication in patients with a history of ACE inhibitor-associated angioedema and bilateral renal artery stenosis. Monitor serum creatinine and potassium regularly. Do not take potassium supplements.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg Tabelts
Losartan Potassium and Hydrochlorothiazide combines a selective AT1 receptor blocker with a thiazide diuretic on the WHO Model List of Essential Medicines. Losartan blocks angiotensin II-induced vasoconstriction and uniquely possesses intrinsic uricosuric properties that increase uric acid excretion, offsetting the hyperuricemic tendency of hydrochlorothiazide, while hydrochlorothiazide reduces extracellular fluid volume. Indicated for the treatment of hypertension not adequately controlled on monotherapy and for reducing stroke risk in hypertensive patients with left ventricular hypertrophy.
Ramipril Tablets 2.5 mg
Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.
Ramipril Tablets 5 mg
Angiotensin Converting Enzyme (ACE) Inhibitor on the WHO Model List of Essential Medicines. It blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, reducing peripheral arterial resistance, decreasing aldosterone secretion, and inhibiting the enzymatic degradation of bradykinin, producing potent vasodilation and cardioprotection. Indicated for essential hypertension, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction, and diabetic nephropathy.
Telmisartan 40mg + Hydrochlorothiazide 12.5mg Tablets
Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.